Achieve Life Sciences, Inc. (ACHV)
NASDAQ: ACHV · Real-Time Price · USD
2.680
-0.070 (-2.55%)
Jul 18, 2025, 4:00 PM - Market closed
Achieve Life Sciences Stock Forecast
Stock Price Forecast
The 3 analysts that cover Achieve Life Sciences stock have a consensus rating of "Strong Buy" and an average price target of $14.33, which forecasts a 434.7% increase in the stock price over the next year. The lowest target is $11 and the highest is $20.
Price Target: $14.33 (+434.7%)
Analyst Consensus: Strong Buy
* Price targets were last updated on Nov 14, 2024.
Analyst Ratings
The average analyst rating for Achieve Life Sciences stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Feb '25 | Mar '25 | Apr '25 | May '25 | Jun '25 | Jul '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 4 | 4 | 4 | 2 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 5 | 5 | 5 | 5 | 5 | 3 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Rodman & Renshaw | Rodman & Renshaw | Strong Buy Initiates $12 | Strong Buy | Initiates | $12 | +347.76% | Nov 14, 2024 |
| Raymond James | Raymond James | Strong Buy Initiates $20 | Strong Buy | Initiates | $20 | +646.27% | Sep 27, 2024 |
| Oppenheimer | Oppenheimer | Buy Reiterates $11 | Buy | Reiterates | $11 | +310.45% | Aug 15, 2024 |
| Oppenheimer | Oppenheimer | Buy Maintains $18 → $11 | Buy | Maintains | $18 → $11 | +310.45% | May 13, 2024 |
| JonesTrading | JonesTrading | Strong Buy Initiates $20 | Strong Buy | Initiates | $20 | +646.27% | Apr 17, 2024 |
Financial Forecast
Revenue This Year
n/a
from 318.79M
Revenue Next Year
n/a
EPS This Year
-1.24
from -1.24
EPS Next Year
-1.21
from -1.24
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | n/a | 26.3M | 124.0M | ||
| Avg | n/a | 17.5M | 106.0M | ||
| Low | n/a | 8.4M | 88.2M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | 607.4% | ||
| Avg | - | - | 504.5% | ||
| Low | - | - | 403.1% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -1.10 | -0.93 | 0.72 | ||
| Avg | -1.24 | -1.21 | -0.13 | ||
| Low | -1.40 | -1.69 | -1.00 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.